DelveInsight’s Barrett’s Esophagus with Dysplasia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Barrett’s Esophagus with Dysplasia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Barrett’s Esophagus with Dysplasia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Barrett’s Esophagus with Dysplasia: Overview
Dysplasia is a pre-cancerous stage in Barrett’s esophagus, where the cell develops abnormal features. However, these abnormal cells do not have the capability to spread to other parts of the body. According to WHO Blue Books, unequivocal neoplastic epithelium without invasion, associated with Barrett esophagus is defined as Barrett’s Esophagus with Dysplasia.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/barretts-esophagus-with-dysplasia-market
Some of the key facts of the Barrett’s Esophagus with Dysplasia Market Report
According to Herrera Elizondo et al., 2018, the overall prevalence of Barrett’s esophagus was 1.8% in a cohort study, with a prevalence of 7.2% in patients that had symptoms of gastroesophageal reflux. Out of the given population, 11.1% of patients with Barrett’s esophagus presented high-grade dysplasia.
According to Herrera Elizondo et al., 2018, Barrett’s Esophagus with Dysplasia prevalence was higher in women than men (62.4% vs. 37.6%).
The incidence of diagnosed BO is increasing, independent of the number of upper gastrointestinal endoscopies that are being performed. This increase in BO incidence will likely result in a further increase in the incidence of esophageal adenocarcinomas in the near future.
Barrett’s Esophagus with Dysplasia market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Barrett’s Esophagus with Dysplasia in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Barrett’s Esophagus with Dysplasia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Barrett’s Esophagus with Dysplasia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Barrett’s Esophagus with Dysplasia Market Insights
Despitethe well-establishedbenefitsof currently approvedproton pump inhibitors (PPIs)in the treatmentofdysplatic BE, the unmet needs are still present and althoughoften frustrating, they challenge clinicians.The unmetneeds relate to the lack of complete control of acid secretion with oral PPI administration in the management of patients with symptoms. To increase the quality of life of these patients and avoid multiple medical consultations and unnecessary investigations, the market islooking forwardtowards new treatments beyond the current regimen.
The treatment for Barrett’s esophagus depends on the degree of dysplasia found in the esophageal cells. The treatment type for Barrett’s Esophagus with dysplasia includes medications and surgical treatment. Medications include proton pump inhibitors, antacids, H2blockers, promotility agents, and others. Surgical therapies include radiofrequency ablation, photodynamic therapy, and endoscopic spray cry therapy, endoscopic mucosalre section, and surgery.
Barrett’s Esophagus with Dysplasia Epidemiology
The epidemiology section covers insights about the historical and current Barrett’s Esophagus with Dysplasia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Barrett’s Esophagus with Dysplasia Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Barrett’s Esophagus with Dysplasia market or expected to get launched in the market during the study period. The analysis covers Barrett’s Esophagus with Dysplasia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Barrett’s Esophagus with Dysplasia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Barrett’s Esophagus with Dysplasia Emerging Therapy Assessment
The pipeline of Barrett’s Esophagus With Dysplasia is not robust in terms of medication products availability in the developmental stage but some devices are actively under preparation for the treatment of dysplastic BE. The market will witness key players in the line of development of promising products such as HOYA Pentax Medical, Japan (Cryoballoon focal ablation system), and many others.
Barrett’s Esophagus with Dysplasia Company includes-
HOYA Pentax Medical, and others
Barrett’s Esophagus with Dysplasia Therapies includes-
CbFAS; C2 Cryoballoon, and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/barretts-esophagus-with-dysplasia-market
Table of content
Competitive Intelligence Analysis
Market Overview at a Glance
Disease Background and Overview
Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints of Barrett’s Esophagus with Dysplasia Treatment
Seven Major Market Analysis
7MM: Market Outlook
Access and Reimbursement Overview
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States